Earnings Report Shows Gilead Can Lower Sovaldi’s Unsustainable Price

By on




July 23, 2014

Contact:   Kelly Peuquet
                 National Coalition on Health Care
                 [email protected]
                 202-638-7151, ext. 106

Statement from the National Coalition on Health Care’s President and CEO John Rother on the latest quarterly earnings report from Gilead Sciences, Inc., manufacturer of the hepatitis C drug Sovaldi:

“It’s clear Gilead has plenty of room to reduce the $1000 per pill price in order to ensure patients have access to this critical treatment. It’s this sort of pricing for drugs needed by millions of Americans that is putting unsustainable pressure on patients and the health care system as a whole.”


The National Coalition on Health Care(NCHC), the oldest and most diverse group working to achieve comprehensive health system reform, is a 501(c)(3) organization representing more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers and groups representing consumers, patients, women, minorities and persons with disabilities. Member organizations collectively represent – as employees, members, or congregants – over 100 million Americans.

Some members of NCHC do not, or cannot, take positions either on specific legislation, strategies or on any policies outside their respective mission areas. However, all that can, do endorse broad policy positions in support of comprehensive health system change.